Literature DB >> 19668016

A novel method to predict the dry eye symptoms in new contact lens wearers.

Heiko Pult1, Paul J Murphy, Christine Purslow.   

Abstract

PURPOSE: Lid wiper epitheliopathy (LWE) and lid parallel conjunctival folds (LIPCOF) give moderate prediction levels for dryness symptoms in experienced contact lens (CL) wearers. This study investigated whether a combination of LWE and LIPCOF plus other tear film tests and subjective evaluation before contact lens fitting was better able to predict CL-induced dry eye (CLIDE) symptoms.
METHODS: Tear meniscus height, non-invasive break-up time (NIBUT), ocular hyperaemia, LIPCOF, phenol red thread test, corneal and conjunctival staining, and LWE of the right eye of 33 new soft CL wearers (12 males, 21 females, median age = 30.5 years; range = 19 to 44) were assessed in a prospective 2-mo longitudinal study. Symptoms were evaluated by the Ocular Surface Disease Index (OSDI) and subjects were grouped according to their response in the Contact Lens Dry Eye Questionnaire (CLDEQ) during the study (20 symptomatic and 13 asymptomatic). The subjects were fitted with vifilcon A and senofilcon A lenses for a 2-week period, consecutively.
RESULTS: Limbal hyperaemia (repeated measures analysis of variance; p < 0.05) and LWE (Friedman; p < 0.004) increased significantly during the study but not LIPCOF (p > or = 0.318; temporal, nasal, and Sum), bulbar hyperaemia (p = 0.432), staining (p > or = 0.060), OSDI (p = 0.126), or CLDEQ (p = 0.317, kappa = 0.279). Limbal hyperaemia significantly decreased in senofilcon A lenses. Wearing comfort among symptomatics was significantly better with senofilcon A (p = 0.005). At the enrolment visit, the subjects who became symptomatic exhibited significantly decreased NIBUT and increased LIPCOF and OSDI (range, p < 0.027). The best test combination to predict CLIDE (logistic regression analyses) was LIPCOF Sum plus NIBUT and OSDI, (positive predictive value = 87% and accuracy = 91%).
CONCLUSIONS: LIPCOF, NIBUT, and OSDI are significant discriminators for CLIDE in new CL wearers compared with hyperaemia, tear meniscus height, phenol red thread test, staining, and LWE. The best test combination is NIBUT plus LIPCOF Sum and OSDI (named the Contact-Lens-Predicting-Test).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19668016     DOI: 10.1097/OPX.0b013e3181b598cd

Source DB:  PubMed          Journal:  Optom Vis Sci        ISSN: 1040-5488            Impact factor:   1.973


  7 in total

Review 1.  [Practical tips and tricks in fitting soft contact lenses].

Authors:  H Pult; R Khaireddin
Journal:  Ophthalmologe       Date:  2013-06       Impact factor: 1.059

2.  The relationship between clinical signs and dry eye symptoms.

Authors:  H Pult; C Purslow; P J Murphy
Journal:  Eye (Lond)       Date:  2011-01-21       Impact factor: 3.775

3.  Sicca complex among Egyptian patients with chronic hepatitis C virus infection.

Authors:  Zeinab Nawito; Amr Amin; Sohier Abu El-Fadl; Khaled Abu El Einen
Journal:  Clin Rheumatol       Date:  2011-04-13       Impact factor: 2.980

4.  Contact lenses wettability in vitro: effect of surface-active ingredients.

Authors:  Meng C Lin; Tatyana F Svitova
Journal:  Optom Vis Sci       Date:  2010-06       Impact factor: 1.973

5.  Associations Between Lid Wiper Microvascular Responses, Lens Fit, and Comfort After One Day of Contact Lens Adaptation by Neophytes.

Authors:  Hong Jiang; Min Fang; Ross Franklin; Ava-Gaye Simms; Zohra Fadli; Jianhua Wang
Journal:  Eye Contact Lens       Date:  2022-05-17       Impact factor: 3.152

6.  OSDI Questions on Daily Life Activities Allow to Detect Subclinical Dry Eye in Young Contact Lens Users.

Authors:  José Ángel Pastor-Zaplana; Fernando Borrás; Juana Gallar; M Carmen Acosta
Journal:  J Clin Med       Date:  2022-05-06       Impact factor: 4.964

7.  Lid Wiper Microvascular Responses as an Indicator of Contact Lens Discomfort.

Authors:  Zhihong Deng; Jianhua Wang; Hong Jiang; Zohra Fadli; Che Liu; Jia Tan; Jin Zhou
Journal:  Am J Ophthalmol       Date:  2016-08-16       Impact factor: 5.258

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.